BioCentury | Sep 21, 2017
Tools & Techniques
On your marks
...the first closing of a series B round in April 2017; Latterell Venture Partners and Wicklow Capital...
...EBV)-positive lymphoma Phase I complete $18.4 (A) Forward Ventures; NantKwest Inc. (NASDAQ:NK); Latterell Venture Partners, Wicklow Capital...
...EBV)-positive lymphoma Phase I complete $18.4 (A) Forward Ventures; NantKwest Inc. (NASDAQ:NK); Latterell Venture Partners, Wicklow Capital...